DBV Technologies to Participate in Upcoming Investor Conference

Nov 22nd, 2022 16:30 EST

Montrouge, France, November 22, 2022

DBV Technologies to Participate in Upcoming Investor Conference

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its participation in the 5th Annual Evercore ISI HealthCONx Conference taking place Nov. 29 – Dec. 1, 2022. Daniel Tassé, Chief Executive Officer, will participate in a Fireside Chat session on Wednesday, Nov. 30, at 8 a.m. ET, as well as one-on-one investor meetings throughout the day.

A live webcast of the fireside chat will be available on the Investors & Media section of the Company’s website: https://wsw.com/webcast/evercore29/dbvt/2371680.

A replay will also be available on DBV Technologies’ website for 90 days after the event.

About DBV TechnologiesDBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, and is DBV Technologies’ method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies’ food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363[email protected]

Media Contact Angela MarcucciDBV Technologies+1 646-842-2393[email protected] 

Viaskin and EPIT are trademarks of DBV Technologies.

Attachment

SHARE

You must be logged in to post a comment.

Related Recent Publications

You must be logged in to post a comment.

Email newsletter

Receive the latest stock news and signals